Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Duncan Livingstone


Recent stories

  • Let’s recap on gliptin DPP-4 inhibitorsSubscription

    PJ, May 2013

    There are currently four agents that inhibit dipeptidylpeptidase-4 available in the UK. Commonly called “gliptins”, they are a relatively new class of drugs. Linagliptin (Trajenta) is still included in the Medicines and Healthcare products Regulatory Agency black triangle scheme, so is being intensively monitored. Sitagliptin (Januvia), saxagliptin (Onglyza) and vildagliptin (Galvu

  • Let’s recap: Rapid-acting insulin secretagoguesSubscription

    PJ, March 2013

    The two rapid-acting insulin secretagogues, nateglinide (Starlix) and repaglinide (Prandin), are not widely prescribed, but are included in the new medicine service. According to the National Institute for Health and Clinical Excellence, these agents might be considered as an alternative to a sulfonylurea for some people with type 2

  • Let’s recap on ACEIs for hypertensionSubscription

    PJ, January 2012

    Angiotensin-converting enzyme inhibitors are used to treat a range of conditions, including high blood pressure, heart failure, diabetic neuropathy and post myocardial infarction. The new medicine service in England can be offered to patients starting a medicine for hypertension but how can you tell that this is the indication when a patient hands you a prescription for an ACE inhibitor? Of course, the patient may be able to confirm this but, if he or she is unsure, other medicines prescribed

  • Let’s recap on antiplatelet agentsSubscription

    PJ, April 2012

  • Let’s recap: Sulfonylureas for type 2 diabetesSubscription

    PJ, November 2012Comments (1)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.